Insiders who reported open-market trades in the last 12 months at the companies Anne McGeorge files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Marino Garcia - $27.96M in DNTH purchases and sales in the last 12 months
Simrat Randhawa - $15.00M in DNTH purchases and sales in the last 12 months
Ryan Savitz - $14.29M in DNTH purchases and sales in the last 12 months
Edward Carr - $5.59M in DNTH purchases and sales in the last 12 months
Adam M. Veness - $4.63M in DNTH purchases and sales in the last 12 months
Jorey Chernett - $2.69M in STLN purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Anne McGeorge is a corporate insider, tracked as Director of Dianthus Therapeutics, Inc. /DE/ (DNTH). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Anne McGeorge submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Anne McGeorge been buying or selling stock?
Recorded transactions: 0 open-market purchases and 5 open-market sales ($845K) across all tracked filings.
Anne McGeorge is Director of Dianthus Therapeutics, Inc. /DE/ (DNTH). 5 SEC Form 4 filings on record going back to 2024, most recently on 11 August 2026. Most recent open-market trade: sold $78K of DNTH on 11 August 2026. Lifetime open-market sales: $845K.
Recent transactions
11
The latest 11 SEC Form 4 transactions reported by Anne McGeorge.
InsiderAlpha's records for Anne McGeorge go back to 2024: 5 primary Form 4 filings, an average of 1.7 per year. 9 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
